Homozygous Familial Hypercholesterolemia Clinical Trial
Official title:
HoFH, the International Clinical Collaborators - A Global HoFH Data-sharing Platform
Homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder caused by bi-allelic mutations in the LDL Receptor pathway, is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth and premature atherosclerotic cardiovascular disease (ASCVD). Our current knowledge about HoFH is disjointed and largely stems from relatively small case series and expert opinion. HICC (Homozygous FH International Clinical Collaborators) is a global consortium of clinicians who are contributing de-identified data of patients diagnosed with HoFH with the goal to advance our understanding of this rare disease.
The HICC registry is an observational, multicenter, international registry collecting de-identified clinical and genetic information from patients with homozygous Familial Hypercholesterolemia (HoFH) worldwide. Patients are eligible to be enrolled in the registry based on the diagnosis of HoFH by the treating clinician, irrespective of how the diagnosis was made. To generate up-to-date data reflecting current rather than historic practice, patients who died or were lost to follow-up prior to 2010 are excluded. Anonymized data on demographics, type of HoFH diagnosis (clinical and/or based on the results of a genetic test), genetic results, (cardiovascular) medical history, relevant family history, physical examination, laboratory measurements, lipid lowering treatment and cardiovascular imaging are collected for 3 different time points: at diagnosis, at enrolment and at time of best lipid profile (if this is different from time at enrolment). Data are collected using pre-definite electronic case report forms to ensure uniformity of data collected. Primary analysis will be cross-sectional (e.g. based on country of residence, age, etc) ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04031742 -
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06009393 -
Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
|
Phase 2 | |
Completed |
NCT03156621 -
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
|
Phase 3 | |
Recruiting |
NCT06125847 -
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
|
Early Phase 1 | |
Completed |
NCT01878604 -
Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia
|
N/A | |
Completed |
NCT01412034 -
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
|
Phase 2 | |
Withdrawn |
NCT02765841 -
Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy
|
Phase 3 | |
Completed |
NCT03933293 -
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH
|
Phase 2 | |
Completed |
NCT00704535 -
Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)
|
||
Recruiting |
NCT02135705 -
LOWER: Lomitapide Observational Worldwide Evaluation Registry
|
||
Completed |
NCT03409744 -
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
Completed |
NCT04233918 -
Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
Withdrawn |
NCT02399852 -
Effects of Lomitapide on Carotid and Aortic Atherosclerosis
|
N/A | |
Terminated |
NCT01841684 -
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
|
Phase 3 | |
Recruiting |
NCT01109368 -
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
|
||
Completed |
NCT01556906 -
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
|
Phase 2 | |
Active, not recruiting |
NCT03135184 -
HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia
|
N/A | |
Completed |
NCT03399786 -
Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
Completed |
NCT03851705 -
A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
|
Phase 3 | |
Completed |
NCT02265952 -
Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
|
Phase 2 |